Released May 6, 2014, after the close
10-Q filed May 6, 2014, 36 days after period end · 0001390478-14-000024
Q1 2014 · 10-Q
Revenue$2.17M$2.17M −21.0% vs Q1 2013+51.3% vs Q4 2013
Net Income-$2.54M-$2.54M N/M vs Q1 2013N/M vs Q4 2013
EPS Diluted-$0.02-$0.02 N/M vs Q1 2013no prior Q4 2013 on file
Operating Income-$11,849,000N/M
Operating Cash Flow-$8,048,000N/M
Free Cash Flowderived-$8,070,000—
Margins · derived
Operating margin-545.3%−304.9 pt vs Q1 2013
Net margin-116.7%+483.0 pt vs Q1 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2014 | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|---|
| Revenue | $2.17M | $2.75M | $2.75M | — |
| Net Income | -$2.54M | -$16.49M | -$10.54M | -$3.84M |
| EPS Diluted | -$0.02 | -$0.11 | -$0.52 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR